The regulatory pendulum in transfusion medicine

Transfusion Medicine Reviews

Volumn 16, Issue 4, 2002, Pages 273-282

  Farrugia, Albert ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD; BLOOD BANK; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; GOVERNMENT; HEALTH ECONOMICS; LAW SUIT; POLICY; POLITICS; PUBLIC HEALTH; QUALITY CONTROL; REGULATORY MECHANISM; REVIEW; GOVERNMENT REGULATION; HUMAN; LEGAL ASPECT; STANDARD;

BLOOD BANKS; BLOOD TRANSFUSION; GOVERNMENT REGULATION; HUMANS; QUALITY CONTROL;

EID: 0036804666     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1053/tmrv.2002.35213     Document Type: Article

References (51)

1. Starr D: Blood - An Epic History of Medicine and Commerce. New York, NY, Knopf 1999, p225
2. European Council Directive 89/381/EEC. Available of http://www.europa.eu.int. Accessed July 3, 2002
3. European Council Directive 75/319/EEC. Available at http://www.europa.eu.int. Accessed July 3, 2002
4. European Commission 2000. Safety of Human Blood: Byrne Welcomes Political Agreement in Health Council. Available at: http://europa.eu.inL/rapid/start/cgi/guesten.ksh?p action. gettxt=gt&doc=IP/01/1594[01] RAPID&Ig=EN. Accessed
5. Miller WV: Controversies in transfusion medicine. Blood banks should use good manufacturing practices and the pharmaceutical manufacturing approach. Transfusion 33:435-438, 1993
6. Office of the US Inspector General (1997) Review of the Food and Drug Administration's Inspection Process of Plasma Fractionators (CIN: A-03-97-O0350). Available of http://waisgate.hhs.gov. Accessed
7. Gaul GW: The loose way the FDA regulates blood industry. Philadelphia Inquirer, Sept 25:1, 1989
8. Titmuss RM: The Gift Relationship: From Human Blood to Social Policy. New York, NY, Pantheon, 1971
9. Hagen P: Blood: Gift or Merchandise. New York, NY, Alan Liss Inc, 1982
10. World Health Assembly: Resolution WHA28.72. Utilization and Supply of Human Blood Products. World Health Organization, Geneva, 1975
11. Waytes AT, Igel H, Zerlauth G, et al: A safer plasma supply from renumerated donors - The Immuno/Community Bio-Resources experiment. Dev Biol 102:37-51, 1999
12. Feldman EA, Bayer R, eds: Blood Feuds - AIDS, Blood and the Politics of Medical Disaster. New York, NY, Oxford University Press, 1999
13. Report of the Krever Commission of Inquiry into the Blood System in Canada 1996. Available at www.hc sc.gc.ca/ENGLISH/PROTECTION/rrever.html. Accessed July 3, 2002
14. HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Washington DC, National Academy Press, 1995
15. Report of the Krever Commission of Inquiry into the Blood System in Canada. Ottawa, Canadian Government Publishing, Vol 1, p 147, 1996
16. HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. National Academy Press, Washington DC 1995, p 226
17. Report of the Krever Commission of Inquiry into the Blood System in Canada. vol 3 p 1049, 1996
18. Leveton LB, Sox HC, Stoto MA, eds: HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. National Academy Press, Washington DC' 1995 p226-227
19. European Commission (2000). Available at: http://europa.eu.int/eurlex/en/com/cnc/2000/com2000-0001 em0l.pdf. Accessed July 3. 2002.
20. Center for Biologics Evaluation and Research: Guidance for Industry. Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products. Available at http://www.fda.gov/cber/guidelines.htm. Accessed July 3, 2002
21. AuBuchon J: How Should the Government Respond to the Current Public Debate over Leukoreduction? Department of Health and Human Services Advisory Committee on Blood Safety and Availability. Available at http://www.hhs.gov/bloodsafety/transcripts/20010125.html. Accessed July 3, 2002
22. Daver EA, ed: Blood Banking and Regulation: Procedures, Problems and Alternatives. National Academy Press, Washington DC, 1996, p 95
23. Centre for Evidence Based Medicine: Available at http://www.cebm.utoronto.ca/intro/whatis.htm. Accessed July 3, 2002
24. Russell LB, Gold MR, Siegel JE, et al: The role of cost-effectiveness analysis in health and medicine. JAMA 276:1172-1177, 1996
25. Finucane ML, Slovic P, Mertz CK: Public perception of the risk of blood transfusion. Transfusion 40:1017-1022, 2000
26. Farrell K, Ferguson E, James V, et al: Confidence in the safety of blood for transfusion: The effect of message framing. Transfusion 41:1335-1340, 2001
27. Allain JP: Will genome detection replace serology in blood screening for microbial agents. Bailliere's Clini Haematol 13:615-629. 2000
28. Busch MP, Stramer SL, Kleinman SH: Evolving applications of nucleic acid amplification assays for viral transmission by blood components and derivatives, in Garratty G (ed). Applications of Molecular Biology to Blood Transfusion Medicine. Bethesda, MD, American Association of Blood Banks, 1997, pp 23-76
29. Schfeiber GB, Busch MP, Kleinman SH, et al: The risk of transfusion-transmitted viral infections NEJM 334:1685-1690, 1996
30. Lee DH. Paling JE, Blajchman MA: A new tool for communicating transfusion risk information. Transfusion 38:184-188, 1998
31. Alter H, Epstein JS, Swenson SG, et al: Prevalence of HIV type I p24 antigen in US blood donors - An assessment of the efficacy of testing in donor screening. NEJM 323:1312-1317, 1990
32. Kessler D: Food and Drug Administration conference on the feasibility of genetic technology to close the HIV window in donor screening. Transfusion 37:346-351, 1994
33. Blood Banking and Regulation: Procedures, Problems and Alternatives. National Academy Press, Washington DC, 1996, p 93
34. CBER: Memorandum to All Registered Blood Establishments - Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen. Available at http://www. fda.gov/cber/bldmem/hiv-ag.pdf. Accessed July 3, 2002
35. Stramer S, Porter RA: Replacement of HIV-1 antigen screening with HIV-1 RNA nucleic acid testing (NAT) for whole blood donations. Transfusion 39:2S, 1999
36. Vamvakas EC: Assessment of the risk of transfusiontransmitted viral infections: Evidence-based practice of transfusion medicine. AABB Press, 2001, p 114
37. CBER: Letter of Manufacturers - Lot Release of Immunoglobulin Products. December 27, 1994
38. EMEA: The Introduction of Nucleic Acid Amplification Technology (NAT) for the Detection of Heaptitis C Virus RNA in Plasma Pools. CPMP/BWP/390/97. Available at http://www. emea.eu.int. Accessed July 3, 2002
39. CBER: Guidance for Industry. Application of Current Statutory Authority to Nucleic Acid Testing of Pooled Plasma. Available at http://www.fda.gov/cber/gdlns/ppnat.htm. Accessed July 3, 2002
40. Stramer S: Application of Nucleic Acid Testing to Blood Borne Pathogens and Emerging Technologies OBRR/CBER/FDA Workshop. Available at http://www.fda.gov/cber/minutes/nuclacd1204pl.pdf. Accessed July 3, 2002
41. Busch MP: Application of Nucleic Acid Testing to Blood Borne Pathogens and Emerging Technologies OBRR/ CBER/FDA Workshop. Available at http://www.fda.gov/cber/minutes/nuclacdl204pl.pdf. Accessed July 3, 2002
42. Nubling M: Application of Nucleic Acid Testing to Blood Borne Pathogens and Emerging Technologies OBRR/ CBER/FDA Workshop. Available at http://www.fda.gov/cber/ minutes/nuclacdl204pl.pdf. Accessed July 3. 2002
43. Heaton A: Application of Nucleic Acid Testing to Blood Borne Pathogens and Emerging Technologies OBRR/CBER/ FDA Workshop. Available at http://www.fda.gov/cber/minutes/ nuclacdl204p2.pdf. Accessed July 3, 2002
44. Hellstern P: Clinical experience with the viral safety of immunoglobulins. Blood Coagulation and Fibrinolysis. 53:S31-34, 1994
45. Suomela H: Inactivation of viruses in blood and plasma products. Transfus Med Rev 8:42-57, 1993
46. Dressler S: Blood scandal and AIDS in Germany, in Feldman EA, Bayer R (eds). Blood Feuds - AIDS, Blood, and the Politics of Medical Disaster. New York, NY, Oxford University Press, 1999
47. Serious Hazards of Transfusion - SHOT. Annual Report 1999-2000. Available at http://www.shot.demon.co.uk/Report%2099-00.doc. Accessed July 3, 2002
48. Dzik S: Leukocyte reduction, in AuBuochon JP, Petz LD, Fink A (eds). In Policy Alternatives in Transfusion Medicine. Fink A. AABB Press, 2001
49. Carish C: Bad Blood. Available at: http://lists.essential. org/pipermail/pbarm-policy/2000-october/000454.html. Accessed July 3, 2002
50. BBC News: Bad blood Spreads AIDS in China. Available at http://news.bbc.co.uk/hi/english/world/asia-pacific/ newsid 1359000/1359670.stm. Accessed July 3, 2002
51. Advisory Committee on Blood Safety Availability. Available at http://www.hhs.gov/bloodsafety/. Accessed July 3,2002